Walking the tightrope
Anticoagulation on ECMO is the single highest stakes balancing act in extracorporeal life support. The circuit wants to clot because blood is in contact with a large foreign surface. The patient wants to bleed because we have anticoagulated them, often after major surgery or major trauma. Get it wrong in either direction and the patient pays for it.
Why the circuit clots
Anywhere blood meets a non endothelial surface, the contact pathway activates. Platelets are sheared and consumed by the pump and the membrane. The membrane lung gradually develops fibrin deposition. The oxygenator pressures drift up. Tiny clots in the circuit become visible clots, and visible clots become a circuit change, an emergency, or worse, an embolic event in the patient.
The job of anticoagulation is to slow that process enough to keep the circuit running while not bleeding the patient out.
What we actually use
Unfractionated heparin remains the workhorse for adult ECMO at most centers. It is cheap, titratable, has a short half life, and has a reversal agent. We dose it as a continuous infusion and follow it with anti Xa levels, activated clotting times, or activated partial thromboplastin times, depending on institutional protocol. Each test has its strengths and its noise.
Bivalirudin has become an increasingly common alternative, especially in patients with heparin induced thrombocytopenia, heparin resistance, or persistent inflammation. It is a direct thrombin inhibitor with a short half life, dosed as an infusion, monitored with PTT or dilute thrombin time. It is more expensive and there is no reversal agent, but it is often more predictable in the inflamed ECMO patient.
The point is not which agent is best in the abstract. The point is that the team has to know the agent it is using, the test it is following, and the targets the medical director has set.
How tight the targets need to be
This is where philosophy meets evidence. Older practice ran ACTs in the 180 to 220 range. Modern practice, especially with newer circuits and centrifugal pumps, often runs lower targets and lower platelet activation. Bleeding is consistently a bigger threat to mortality than thrombosis in modern series.
Specific targets vary, but the principle does not. Pick a target range. Monitor it on a schedule, not just when something looks wrong. Adjust slowly. Review trends, not single values. Communicate every change at handoff.
What to watch at the bedside
The lab numbers matter, but so do the patterns you can see. New blood at the cannula sites. A drop in hemoglobin without an obvious source. Hematuria. New neurologic changes. A rising delta pressure across the oxygenator. Visible clot in the circuit, especially at the inlet of the pump or the post oxygenator side. A platelet count that is dropping faster than the rest of the picture explains.
Any one of those should trigger a conversation with the team. Two of them at the same time should change something on the next round.
Special situations
Several scenarios deserve their own paragraph. Postoperative cardiac surgery patients often need lower anticoagulation in the first 24 hours to allow surgical hemostasis. Trauma patients with intracranial injury sometimes run with no heparin at all, accepting a higher circuit risk to protect the brain. Patients with HIT need an alternative agent immediately. Pediatric and neonatal patients have their own targets and their own bleeding risks, particularly intracranial in the smallest neonates.
In every case, the answer is not a recipe. It is a daily conversation between the ECMO specialist, the intensivist, the surgeon, and the bedside team. We write down the target, we write down the plan if we miss it, and we write down what we will do if the patient bleeds or the circuit clots.
The bottom line
Anticoagulation on ECMO is not solved. It is managed. The teams that do it well are the teams that respect both sides of the tightrope and never assume yesterday's plan still fits today's patient.